Insilico Medicine has received FDA clearance for ISM8969, an orally available NLRP3 inhibitor, to treat Parkinson's Disease. The Phase I clinical trial will assess safety, tolerability, and pharmacokinetics in healthy volunteers. ISM8969, developed using AI, targets chronic neuroinflammation associated with neurodegenerative disorders.
InSilico MedicineJan 23 2026 Insilico Medicine , a clinical-stage drug discovery and development company driven by generative artificial intelligence , today announced that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has recently received investigational new drug clearance from the U.
S. Food and Drug Administration , intended for the treatment of Parkinson's Disease. The Phase I clinical trial plans to evaluate the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers, and to identify the optimal dose level to be recommended for further investigation. NLRP3 has emerged as a key contributor to chronic neuroinflammation and disease progression in neurodegenerative disorders. A novel NLRP3 inhibitor, ISM8969 with the desired brain penetrant property made possible via our AI-powered design process, offers the potential to advance Parkinson's Disease treatment to the next generation. We are excited to get the greenlight from FDA to advance this novel therapeutic to human clinical trials, and we hope to induce a genuine paradigm shift with AI breakthrough in novel drug discovery." Carol Satler, MD, PhD, Senior Vice President for Clinical Development, Non-Oncology, Insilico Medicine Excessive activation of NLRP3 triggers overproduction of pro-inflammatory cytokines and chemokines, resulting in sustained inflammation and tissue damage. By inhibiting NLRP3, ISM8969 aims to modulate this pathological inflammation, supporting neuronal survival and function among patients with neurodegenerative diseases. In December 2024, ISM8969 was nominated as an orally administered, potential best-in-class preclinical candidate targeting NLRP3. It is worth noting that ISM8969 was discovered and optimized using Insilico's Chemistry42, the comprehensive generative chemistry engine consisting of multiple applications across the drug design and discovery stages. More importantly, with the ability to cross the blood-brain barrier and reach the central nervous system directly, ISM8969 establishes its distinctive advantage against CNS disorders including Parkinson's Disease, apart from a balanced druggability profile and efficacy against inflammation in both inflammatory and chronic disease mice models. Related StoriesTo accelerate the global development of ISM8969, Insilico Medicine has entered into a co-development collaboration agreement with Hygtia Therapeutics. Under the agreement, Insilico grants Hygtia Therapeutics worldwide rights to research, develop, register, manufacture, and commercialize ISM8969, with both parties each holding 50% of the global rights and interests to the program. In return, Insilico is eligible to receive up to $66 million in upfront and milestone payments. Based on its comprehensive portfolio empowered by Pharma.AI, Insilico has achieved dozens of collaborations with global leading pharma companies including Sanofi, Lilly, Exelixis and Menarini, and the three key license-out deals sum up to a maximum total contract value of up to US $2.1 billion. Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires an average of 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline-from project initiation to preclinical candidate nomination-of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.
Insilico Medicine Parkinson's Disease NLRP3 Inhibitor Drug Discovery Artificial Intelligence
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Unfolding the role of Hsp70 chaperones in neurodegenerationNeurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis (ALS) affect millions of people worldwide, yet treatments remain largely limited to symptom management.
Read more »
Omeprazole NHS patients urged know warning signs of four side effectsAnyone using the medicine for their stomach problems needs to know about four 'serious' side effects
Read more »
FDA warns consumers about fake cancer cures sold onlineBeware of products claiming to cure cancer on websites or social media platforms, such as Facebook and Instagram. According to Nicole Kornspan, M.P.H., a consumer safety officer at the U.S. Food and Drug Administration (FDA), they're rampant these days.
Read more »
‘Ultimate insult’: Mother of war hero Ben Parkinson blasts Trump for saying Britain stayed away from front linesThe mother of former British paratrooper Ben Parkinson has been left “stunned” by Donald Trump’s comments after the US President insisted Nato troops had avoided the frontline in Afghanistan.
Read more »
Mother of soldier injured in Afghanistan tells LBC Trump's comments are 'an absolute disgrace'The mother of former British paratrooper Ben Parkinson has branded Donald Trump’s claims Nato troops avoided the frontline in Afghanistan an 'absolute disgrace.'
Read more »
New AI-driven method enables precise design of highly efficient custom enzymesEnzymes with specific functions are becoming increasingly important in industry, medicine and environmental protection.
Read more »